Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
Published inSwiss medical weekly, vol. 150, w20375
Publication date2020-11
First online date2020-11-24
Abstract
Keywords
- Dihydrouracil Dehydrogenase (NADP) / genetics
- Drug Monitoring
- Genotype
- Humans
- Pharmacogenetics
- Switzerland
- Fluoropyrimidines
- 5-fluorouracil
- Capecitabine
- DPYD
- Therapeutic drug monitoring
- Chemotherapy
- Pharmacogenomics
- Precision medicine
- Guidelines
Research group
Citation (ISO format)
HAMZIC, Seid et al. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. In: Swiss medical weekly, 2020, vol. 150, p. w20375. doi: 10.4414/smw.2020.20375
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
- PID : unige:159481
- DOI : 10.4414/smw.2020.20375
- PMID : 33232506
Commercial URLhttps://smw.ch/article/doi/smw.2020.20375
ISSN of the journal0036-7672